Washington Trust Advisors Inc. Decreases Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Washington Trust Advisors Inc. lowered its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 0.3% in the 4th quarter, HoldingsChannel reports. The fund owned 29,290 shares of the biopharmaceutical company’s stock after selling 89 shares during the period. Regeneron Pharmaceuticals accounts for about 1.7% of Washington Trust Advisors Inc.’s holdings, making the stock its 17th biggest position. Washington Trust Advisors Inc.’s holdings in Regeneron Pharmaceuticals were worth $20,864,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in REGN. State Street Corp grew its holdings in Regeneron Pharmaceuticals by 1.3% during the 3rd quarter. State Street Corp now owns 4,902,404 shares of the biopharmaceutical company’s stock valued at $5,153,603,000 after buying an additional 61,277 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its position in shares of Regeneron Pharmaceuticals by 3.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 695,799 shares of the biopharmaceutical company’s stock valued at $495,639,000 after acquiring an additional 22,538 shares during the last quarter. Swiss National Bank boosted its position in shares of Regeneron Pharmaceuticals by 0.6% during the 3rd quarter. Swiss National Bank now owns 321,600 shares of the biopharmaceutical company’s stock valued at $338,079,000 after acquiring an additional 2,000 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. boosted its position in shares of Regeneron Pharmaceuticals by 0.4% during the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 302,616 shares of the biopharmaceutical company’s stock valued at $215,562,000 after acquiring an additional 1,108 shares during the last quarter. Finally, National Pension Service boosted its position in shares of Regeneron Pharmaceuticals by 4.0% during the 4th quarter. National Pension Service now owns 232,450 shares of the biopharmaceutical company’s stock valued at $165,581,000 after acquiring an additional 8,833 shares during the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently issued reports on REGN shares. Leerink Partners upgraded Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating and lifted their price target for the company from $762.00 to $834.00 in a research report on Wednesday, February 5th. Truist Financial dropped their price target on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating for the company in a research report on Wednesday, January 8th. Robert W. Baird dropped their price target on Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating for the company in a research report on Wednesday, February 5th. Canaccord Genuity Group downgraded Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, December 17th. Finally, Citigroup dropped their target price on Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating for the company in a research report on Tuesday, January 28th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $973.13.

Regeneron Pharmaceuticals Stock Up 1.7 %

Shares of REGN opened at $687.15 on Thursday. Regeneron Pharmaceuticals, Inc. has a 52 week low of $642.00 and a 52 week high of $1,211.20. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. The company has a market capitalization of $75.12 billion, a price-to-earnings ratio of 17.95, a PEG ratio of 2.34 and a beta of 0.08. The stock’s 50-day moving average price is $696.58 and its 200-day moving average price is $857.92.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $11.21 by $0.86. The company had revenue of $3.79 billion for the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. Regeneron Pharmaceuticals’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same quarter in the prior year, the business posted $11.86 earnings per share. On average, sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th will be issued a dividend of $0.88 per share. The ex-dividend date is Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.51%. Regeneron Pharmaceuticals’s payout ratio is currently 2.30%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.